81 results about "Zonulin" patented technology

The present invention relates to an antibody-like protein based on the tenth fibronectin type III domain (¹⁰Fn3) that binds to serum albumin. The invention further relates to fusion molecules comprising a serum albumin-binding ¹⁰Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.

The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.

Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide.

The present invention provides materials and methods for the treatment of diabetes. Using the materials and methods of the invention, the loss of pancreatic β-cells can be slowed and/or prevented. In addition, the materials and methods of the invention can be used to regenerate pancreatic β-cells.

The invention discloses a fusion protein for Micrococcus pyogenes surface protein, and also discloses the method for preparing the same as well as its usage. The fusion protein is fused by Micrococcus pyogenes fnb and thioredoxin Trx on expression carrier, and the process comprises preparation of Micrococcus pyogenes surface protein fnb coding gene, colony of fnb coding gene into expression carrier and protein fusion. The fusion protein is soluble protein and retains immunity of natural protein. It is detected that said fusion protein is characterized by good response for humoral immunity and cell immunity, enlargement of protection range of protein vaccine and prevention of infection caused by most of Micrococcus pyogenes.

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

An isolated, altered fibronectin-binding protein (Fnb) of S. aureus having at least one mutation in an amino acid selected from residues corresponding to Gln103, Gln105, Lys157, Lys503, Lys620, Lys702, Lys762, Gln783 and Gln830 of FnbA of S. aureus strain ATCC49525 is described. Replacement of these reactive residues within the fibronectin-binding protein renders this protein less capable than wild-type Fnb of covalently cross-linking with fibronectin and fibrin. The altered fibronectin-binding protein effectively interferes with adhesion of S. aureus to fibronectin and fibrin, and therefore, an immunogenic composition comprising such altered Fnb exhibits improved immunogenic properties and is safer to use.

The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist.

The invention discloses a Mycoplasma bovis alcohol dehydrogenase gene, having a nucleotide sequence shown as SEQ ID NO: 1. The invention also discloses a protein coded by the Mycoplasma bovis alcohol dehydrogenase gene; the protein has an amino acid sequence shown as SEQ ID NO: 2 and belongs to the technical field of prevention and treatment of animal infectious diseases and biology. The protein, as a recombinant protein herein, has alcohol dehydrogenase activity, can attach to EBLs (embryonic bovine lung cells), can combine with bovine Fn (fibronectin), has good immunogenicity and reactogenicity, is a virulence-related protein of Mycoplasma bovis, and has a good application prospect in the research on pathogenesis of Mycoplasma bovis, and the research and development of vaccines and diagnostic reagents.

The invention discloses a recombinant human fibronectin III1-C (rhFNIII1-C), and a preparation method and application thereof. The preparation method comprises the following steps: optimizing a targetgene segment of the target protein according to codon expression preference, and inserting the obtained gene segment into pET-32a to construct a recombinant plasmid; transforming and introducing therecombinant plasmid into an expression vector BL21(DE3), and carrying out screening to obtain positive clone bacteria capable of realizing efficient soluble expression; carrying out enlarging fermentation culture on the positive clone bacteria, carrying out induced expression, performing crushing and centrifuging to obtain a supernatant, and carrying out purification through elution with a His-tagaffinity chromatography column, dialysis, filtration and other steps to obtain a high-quality rhFNIII 1-C solution with a protein concentration of 1.0 mg/mL or above and a purity of 90% or above. According to detection and observation results of cell adhesion promoting tests, the rhFNIII1-C has the performance of obviously promoting adherence and adhesion of MDBK cells and Balb/c/3T3 cells and rapid division and growth of the cells, which indicates that the rhFNIII1-C has huge potential of being used as a raw material and a finished product for cosmeceuticals and medical skincare.

The invention relates to polypeptide face-firming repairing essence and a preparation method thereof. The essence is prepared from the following components of, according to the following percentage, 8% of butanediol, 1% of betaine, 0.9% of glyceryl polyacrylate, 1.1% of glycerinum, 2% of lactobacillus, 2% of rice fermentation products, 1% of radix ginseng rubra (PANAXGINSENG) extract, 0.5% of 3-o-ethyl ascorbic acid, 0.4% of acetyl hexapeptide-8, 0.4% of palmitoyl pentapeptide-4, 0.3% of fullerene, 0.3% of decapeptide-4, 0.3% of glycoprotein, 0.3% of fibronectin, 0.3% of bifida ferment lysate, 0.3% of peony (PAEONISASUFFRUTICOSA) root extract, 0.2% of arginine, 0.2% of lactobacillus ferment lysate, 0.2% of hydrolyzed collagen, 0.2% of euglena gracilis (EUGLENAGRACILIS) polysaccharide, 0.2% of radix gentianae (GENTIANASCABRA) extract, 0.2% of chlorella vulgaris (CHLORELANACABRA) extract, 0.2% of crocus sativus (CROCUSSATIVUS) extract, 0.2% of caprylhydroxamic acid and the balance water. The essence has an obvious moisturizing effect, can be used for a long time, has no side effect, is good in effective component extracting effect, and is suitable for industrial production.

A method for prevention of delaying the onset of diabetes using peptide antagonists of zonulin, is disclosed.

A recombinant protein is disclosed, and is constructed by connecting a transdermal peptide to fibronectin through a connecting peptide to form a recombinant transdermal fibronectin, then performing E174D and P292G site mutation on an amino acid sequence of the recombinant transdermal fibronectin to construct a recombinant transdermal fibronectin mutant, with the amino acid sequence of the recombinant transdermal fibronectin mutant being as shown in SEQ ID No.1, and connecting the flexible tail end of the recombinant transdermal fibronectin mutant to an elastase inhibitory peptide through a connecting peptide. The recombinant protein provided by the invention has better stability, the effect is guaranteed, the preparation is simple and convenient, the cost is lower, and the application of the fibronectin and the collagenase inhibitory peptide in cosmetics is greatly expanded.

The invention discloses a recombinant transdermal fibronectin mutant, which is obtained by connecting a transdermal peptide with fibronectin through a connecting peptide to form recombinant transdermal fibronectin, and then performing site mutation on N138Q, E174D, G230V and P292G sites of the amino acid sequence of the recombinant transdermal fibronectin, with the amino acid sequence of the recombinant transdermal fibronectin mutant being shown as SEQ ID No.1. The recombinant protein provided by the invention has better stability, the effect is guaranteed, the preparation is simple and convenient, the cost is lower, and the application of the fibronectin and the collagenase inhibitory peptide in cosmetics is expanded.

The invention discloses a fibronectin (FN) oral agent for preventing and curing gastric and intestinal ulcers. The FN oral agent is characterized by comprising the following components in percentage by weight: 0.05-0.20% of FN, 0.01-0.15% of active small molecule peptide, 1-5% of lysyme, 10-20% of sweetening agent and the balance of water. The FN oral agent disclosed by the invention takes the bioactive ingredient, namely FN, as a core functional component assisted by the active small molecule peptide, lysyme, xylitol and the like, so that the FN oral agent can effectively promote proliferation of mucous epithelium and cells, can participate in cell metabolism and activate the cells, and not only can effectively cure peptic ulcers including gastric ulcer, duodenal ulcer and the like, but also can achieve effects of resisting aging, maintaining beauty, improving immunity and the like.

The invention relates to an inhibitor polypeptide compound targeting elastin derived peptides (EDPs) and application of the inhibitor polypeptide compound. The polypeptide compound contains the following parent peptides represented by amino acid sequences: R1-Val-Xa2-Gly-Ser-Pro-Ser-Ala-Gln-Xa9-Xa10-Ala-Ser-Pro-Xa14, and has the characteristics of better biological activity, safety, higher stability, high synthesis yield, low cost and the like. The polypeptide compound can be used for treating fibrosis diseases accompanied by hepatic fibrosis and hepatic diseases as well as fibrosis diseases accompanied by idiopathic pulmonary fibrosis and lung diseases.